The Cancer Drug Development Forum (CDDF) is an international organisation registered in Austria, providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.
Established in 2001 as the Biotherapy Development Association (BDA), the focus was initially around immunotherapy. Recognizing the importance of embracing all forms of oncology drug development, the name of the organization was changed in 2014 to the Cancer Drug Development Forum (CDDF).
CDDF is a unique organization leveraging a multi-stakeholder approach with the goal of creating an ideal scientific, regulatory and commercial environment for the clinical development of cancer drugs. The mission is to provide a unique platform to facilitate interactions between all stakeholders to improve the efficiency of cancer drug development. It unites experts from academia, the pharmaceutical industry, regulatory authorities (including the EMA and FDA), payers (health technology assessors) and patient advocates.
At regular meetings and workshops, the CDDF encourages a unique collaborative approach, where delegates engage in ‘frank and open’ discussions exploring innovative ideas in a ‘protected’ environment.
Every 18 months we hold the CDDF Alpine Conference with the goal to discuss together with experts from all parties the latest challenges in oncology drug development. Some topics addressed at the Alpine conference will then lead to further workshops during the year.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!